Skip to main content
. Author manuscript; available in PMC: 2019 Jun 15.
Published in final edited form as: J Immunol. 2018 May 2;200(12):4170–4179. doi: 10.4049/jimmunol.1701465

Figure 1. MiR-155 is indispensable for CD4+ Tconv cell-mediated aGVHD.

Figure 1

B6D2F1 recipient mice were lethally irradiated (1100cGy) and transplanted with 10×106 T cell-depleted B6 WT BM cells plus 1×106 CD4+ Tconv cells from GFP expressing miR-155−/− or GFP-B6 WT donors. (A) Kaplan-Meier curve of overall survival, with the median survival of recipients of BM + WT naïve CD4+ Tconv cells (n=13) of 42 days as compared to 100% survival of all recipient mice of miR-155−/− CD4+ Tconv cells (n=13) on day 100. (B) Clinical scores. Data for survival and clinical score is a combination of two independent experiments with n=5-7 mice per group. (C) Representative histopathologic images from recipient mice at time of euthanasia. Arrows highlight areas of tissue inflammation. All images at 400× magnification and stained with H&E. (D) Pathology scores for liver and gastrointestinal tract (GI) from recipient mice at time of euthanasia. Data expressed as mean ± SD. One of two independent experiments shown. For all panels, NS p>0.05, * p<0.05, ** p<0.01, and *** p<0.001.